Abraxis gets tentative generic Kytril OK |
|
|
|
Published
:
Tue, 11 Sep 2007 13:19
|
SCHAUMBURG, Ill. (AP) - Biotechnology company Abraxis BioScience Inc. said its hospital business Abraxis Pharmaceutical Products received tentative Food and Drug Administration approval for generic Kytril.The injectible drug is made by Hoffmann-La Roche and treats side effects from cancer therapy including nausea and vomiting. Roche's patent is set to expire either Dec. 29. or June 28, if the company receives pediatric exclusivity for the drug.Barr Pharmaceuticals Inc. has also received tentative approval for a generic version of the drug.Shares of Abraxis closed at $21.73 Monday.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2371.58 |
-19.70 (
-0.82 %)
|
| SYMBOL (
2010-03-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
12:35pm )
|
|
2650.00 |
+52.00 (
2.00 %)
|
|
WHITBREAD
(
12:35pm )
|
|
1540.00 |
+21.00 (
1.37 %)
|
| SYMBOL (
2010-03-19 )
|
| LAST |
CHANGE
|
| SYMBOL (
2010-03-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
India's Biocon to market Abraxis' breast cancer drug Abraxane in Asia 